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A B S T R A C T 
 
Objectives: HPV16-positive oropharyngeal cancer (OPC) patients experience better outcomes compared to HPV16-negative patients. Currently, strategies for treatment 
de-escalation are based on HPV status, smoking history and disease stage. However, the appropriate cut-point for smoking and the role of other non-clinical factors in 
OPC survival remains uncertain. 
Materials and Methods: We examined factors associated with OPC outcome in 321 patients recruited in a large European multi-center study. Seropositivity for HPV16 E6 
was used as a marker of HPV16 positive cancer.  Hazard ratios (HR) and confidence intervals (CI) were estimated using Cox proportional models adjusted for potential 
confounders. 
Results: Overall 5-year survival following OPC diagnosis was 50%. HPV16-positive OPC cases were at sig- nificantly lower risk of death (aHR = 0.51, 95% CI: 0.32–0.80). 
A significant  effect on OPC survival  was ap-  parent for female sex (aHR 0.50: 95% CI: 0.29–0.85) and being underweight at diagnosis (aHR: 2.41, 95% CI: 1.38–4.21). A 
10 pack year smoking history was not associated with overall survival. Higher stage at diagnosis appeared as the only factor significantly associated with OPC 
recurrence (aHR: 4.88, 95% CI: 2.12–11.21). 
Conclusion: This study confirms that HPV16 status is an independent prognostic factor for OPC survival while female sex lowers risk of death and being underweight at 
diagnosis increases the risk of death. Smoking was not an independent predictor of OPC survival 
 
Abbreviations: AJCC, American Joint Committee on Cancer; ARCAGE, the Alcohol Related Cancers and Genetic susceptibility in Europe study; CI, confidence intervals; HPV, human 
papillomavirus; HR, hazard ratios; OPC, oropharyngeal cancer 
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Introduction 
 
Cancers arising in the oral cavity and pharynx have an estimated global burden of 442,760 incident cases and 241,458 deaths each year [1]. 
Tobacco smoking and alcohol consumption explain nearly 70% of these cancers [2,3]. Infection by Human PapillomaVirus (HPV), speci- fically type 
16 (HPV16) causes a subset of cancers, particularly those arising at the tonsil, oropharynx, soft palate and base of the tongue (collectively referred to 
as oropharyngeal cancers-OPC) [4]. Further, HPV16-positive (HPV16+) OPC is described to be epidemiologically, molecularly and clinically distinct 
from HPV16-negative (HPV16-) OPC [5]. The increasing incidence of OPC in several Western countries is attributed to the increasing HPV16+ 
fraction [6–9]. 
Since HPV16+ OPC patients experience better survival outcomes compared to HPV16- patients, alternative staging has been re- commended 
[10]. However, recurrence remains a concern and it is presently unclear which patients may benefit from de-intensified treatment. Clinically, HPV 
status is ascertained based on HPV DNA and p16 expression or p16 expression alone. HPV status in combination with disease stage and patient 
smoking history (based on a 10 or 20 pack year cut off) has been suggested to classify patients into prognostic groups and to identify candidates for 
de-escalation of treatment [10,11]. This scheme has rarely been verified. Further, the appropriate cut-point for pack years of smoking remains 
uncertain. In addition, the role of other non-clinical risk factors in OPC survival is not fully un- derstood. 
To address these knowledge gaps, we tested 321 oropharyngeal tumors in a large series of well characterized European patients for HPV16 
serology. In addition, HPV16 DNA, p16 expression were tested in the corresponding tumor tissues when available (n = 198). Applying rigorous 
 
 
 
protocols of sample processing; we aimed to evaluate the role of HPV16 and other risk factors in predicting OPC survival and recur- rence. 
 
Methods 
This analysis was based on cases from the European Alcohol Related Cancers and Genetic susceptibility in Europe (ARCAGE) study, con- ducted 
across 10 countries in Europe using a standardized protocol [12]. Briefly, over 2000 incident cases of the oral cavity, pharynx,  larynx, esophagus and 
matched controls were recruited during 2002 to 2005. This analysis included squamous cell carcinoma of ICD-O diag- noses C01, C02.4, C05.1- C05.2, 
C09, C10. All participants underwent personal interviews to record lifestyle exposures. All cases were histo- logically or cytologically confirmed 
primary cancers, and cancer stage was ascertained based on the sixth edition of the staging atlas devel- oped by the American Joint Committee on 
Cancer (AJCC). Tobacco use was broadly categorized as ever or never smokers, ever smokers were defined as individuals who smoked any tobacco 
product at least once a week for a year. Pack years were calculated for all types of tobacco smoking based on cigarette equivalents. Ever drinkers 
were those who reported ever consumption of any alcoholic beverage and the con- sumption of all types of alcoholic beverages was estimated and 
the total frequency was expressed in terms of drinks of alcohol per day [13]. A weighted composite score of oral hygiene and dental care was con- 
structed as described previously [14] and included denture wear, age at start of denture-wearing and gingival bleeding. A weighted dental care 
score was also constructed by combining the frequency of tooth cleaning, use of toothpaste, toothbrush or dental floss and frequency of dentist visits, 
where the maximum score of eight reflected poor dental care. Body mass index was calculated based on weight measured at the time of recruitment. 
BMI ranging from 18.5 to 25.0 was considered normal, below 18.5 underweight while > 25.0 was considered over- weight. Informed consent was 
obtained from all participants in the study and the study was approved by the ethical review boards at the participating centers. 
Pretreatment serum samples were tested for HPV antibodies using the bead-based multiplex serology method [15,16]. We have previously 
shown that HPV16 E6 antibody is a highly specific marker of HPV16+ OPC with false-positive rates less than 1% [15,17–19]. In addition, other 
published reports have demonstrated a high sensitivity and spe- cificity for HPV16 E6 serology with false negatives rates of 5–10% based on the 
definition of gold standard, with stringent definitions having improved rates [20,21]. Here for comparison, 198 available paraffin-embedded OPC 
tumor blocks were tested based on p16 ex- pression and HPV DNA and compared with HPV16 E6 serology. p16 expression was qualitatively 
evaluated using the CINtec Histology P16INK4a Kit (9511, mtmlabs) following manufacturer’s instructions. Expression was scored based on the 
percentage and intensity of nuclear or cytoplasmic staining. A combined score of 4 or greater was con- sidered positive for p16INK4a overexpression 
[15,22]. We have pre- viously demonstrated that this scoring system remains comparable to the more widely used percentage of nuclear and 
cytoplasmic staining cutoff [15,23–25]. HPV genotyping was performed using the Type- Specific E7 PCR bead-based multiplex assay (TS-E7-MPG, 
IARC, France) to detect all high-risk HPV types (HPV16, -18, -26, -31, -33, -35, -39, 
-45, -51, -52, -53, -56, -58, -59, -66, -68a, -68b, -73, and -82) and three 
low-risk HPV types (HPV6, -11, and -70). Briefly, the reporter fluores- cence was quantified using Luminex reader 200 (Luminex Corporation, 
Austin, TX), and cutoffs were computed by adding 5–1.1 multiplied by the median background value expressed as median fluorescence in- tensity 
[15,26]. Given that HPV serology was available on all cases and the previously demonstrated high sensitivity and specificity against the tumor 
HPV16 status, we defined a HPV+ tumor as HPV16 E6 antibody positive. 
The participants of this study were initially recruited during 2002–2005. Subsequently, a one-time retrospective follow up was conducted 
between 2012 and 2015 to obtain last known vital status (alive, death or lost to follow-up) and date of last contact. Mortality data including cause 
and date of death were obtained from at least two information sources for 75% of cases, and one source for the remaining 25%. In Prague and 
Aviano follow-up was completed by review of medical charts alone. In all other centers, medical chart reviews to- gether with information from 
population-based registries at the re- gional or national level were used. In Athens, Barcelona and Manchester physicians were contacted to obtain 
patient outcome in- formation, while in Oslo, Zagreb and Glasgow cancer registries were consulted. In Bremen, Turin, Padova and Dublin 
mortality registries were examined. End of follow-up was defined as the date of last con- firmed contact, vital status at censor, or date of death (if 
applicable). Over 96% of OPC patients' recruited in the study have complete follow- up. Overall survival (all-cause mortality) was evaluated using 
Cox proportional hazard models, predictors were explored for OPC overall and stratified by stage, sex and HPV16 status. Multivariate cox pro- 
portional hazards models were used to estimate HR and 95% CI for HPV16 E6 serology, sex, age, smoking status, alcohol use, dental care, BMI, 
stage while additional adjustment for the center of recruitment was performed. Mortality was also explored using Kaplan Meier curves. The joint 
effects on survival were considered by combining cofactors in interaction models. Recurrence data were available on all 321 cases however 
recurrence date was missing for 61 subjects. Therefore these analysis were restricted to 260 cases. We used chi-squared tests to ex- amine 
heterogeneity in hazard estimates. All statistical analyses were performed using STATA statistical software, version 11 (StataCorp, College Station, 
TX), and all reported P values are two sided. Statistical significance was set at P less than 0.05. 
 
Results 
Subjects were primarily male (77%), ever smokers (90%), alcohol drinkers (97%) and had a median age at diagnosis of 58. The vast majority of OPC were diagnosed 
at late stages; 49% in Stage IV, 25% in stage III and 26% in stages I and II. 31% of OPC cases were HPV16 E6 positive. OPC subjects were followed for 1257 
person years during which 175 deaths occurred (mean follow-up of 3.92 years), of which 98 (56%) were due to head and neck cancer. Overall 5-year survival 
following OPC diagnosis was 50% (95% CI: 43.9–54.9). As described in Table 1, in the univariate analyses there was significantly lower risk of death among 99 
HPV16+ compared to 222 HPV-OPC (HR=0.49, 95%CI: 0.34–0.70). Five-year overall survival was 65% among HPV16+ compared to only 43% among HPV16- 
OPC (p < 0·001, Fig. 1a). Other significant risk factors associated with OPC survival overall in the univariate analysis included female sex (HR 0.52, 95% CI: 0.35–
0.78), older age at diagnosis (HR: 1.24, 95% CI: 1.05–1.45), smoking (HR 2.24, 95% CI: 1.39–3.60), alcohol use (HR: 1.53, 95% CI: 1.13–2.06), moderate dental 
care (HR: 1.58, 95% CI: 1.10–2.29), being underweight at diagnosis (HR: 2.25, 95% CI: 1.38–3.67) and late stage disease (HR: 2.84, 95% CI: 1.78–4.55) (Table 1). 
When these covariates were combined in a single model, the risk of death remained significant lower among HPV16+ compared to HPV16- OPC (aHR: 0.51, 95%CI: 
0.32–0.80, Table 1). In addition, a significant effect on OPC survival was apparent for female sex (aHR 0.50: 95% CI: 0.29–0.85), being underweight at diagnosis 
(aHR: 2.41, 95% CI: 1.38–4.21) and higher disease stage (aHR: 2.63, 95% CI: 1.61–4.03), but not for smoking (HR: 1.11, 95% CI: 0.59–2.09), moderate dental care 
(aHR: 1.09, 95% CI: 0.72–1.65), age (HR:1.17, 95% CI: 0.95–1.44) or alcohol use (HR: 1.02, 95% CI:0.69–1.51) (Table 1). We examined the association these risk 
factors for OPC stratified by HPV16 status, and no observed no heterogeneity (supplementary Table 2). We further examined the robustness of the associations of 
being female or being underweight and OPC survival. No difference was observed in the association between being female and OPC survival among HPV16+ (HR: 
0.34, 95% CI: 0.11 1.08) or HPV16- OPC (HR: 0.57, 95% CI: 0.31 1.05, (P-heterogeneity: 0.61). Conversely, the increased risk of death associated with being 
underweight at diagnosis was consistent for stage I and II (HR: 1.51, 95% CI: 0.17–13.30), stage III (HR: 4.94, 95% CI: 1.77–13.81) and stage IV disease (HR: 2.22, 
95% CI: 1.08–4.55), with no heterogeneity in the estimates (p for heterogeneity: 0.39). We further examined these findings in the context of the recently proposed 
staging for HPV+ OPC that combines disease stage at diagnosis, age and smoking pack-years into four groups with differing prognosis; group I comprising of stage I-
 
 
 
III OPC patients’ with ≤20 pack years, group II of stage I-III patients’ with>20 pack years, group III were stage IV and ≤70 years old and group IV were stage IV 
with>70 years of age [10]. Consistent with the initial report, overall survival decreased across these groups (supplementary Table 3). Notably, female sex (HR: 0.54, 
95% CI: 0.33–0.88) and being underweight at diagnosis (HR for: 2.59, 95% CI: 1.50–4.46) remained consistently associated with OPC survival, independent of the 
suggested prognostic risk classification. Unlike previously published studies, the lack of association of smoking with overall survival following OPC diagnosis was 
consistent (supplementary Table 1). Although metrics of smoking exposure were associated with higher risk of death among OPC patients’ in the univariate analysis 
(e.g. HR for 10 pack year cut-point: 2.24, 95% CI: 1.39–3.60), none of the associations remained significant in the multivariable models. Inclusion of stage and 
HPV16 status in the models significantly mitigated the effect for smoking (bHR for 10 pack year cutpoint: 1.46, 95% CI: 0.80–2.69). Further, we observed no 
interaction between smoking and HPV16 status in the risk of death following OPC diagnosis (P-interaction: 0.50). However, it remains to be noted that the number of 
subjects with less than 10 pack years of smoking were limited, and therefore the absence of an association could be due to limited power. There were 84 recurrences 
among 260 cases with an average followup of 4.2 years. The risk of recurrence was lower in 82 HPV16+ than 178 HPV16- OPC (HR: 0.59; 95% CI: 0.36–0.96, aHR: 
0.55; 95% CI: 0.29–1.06, Table 2). Three year recurrence-free survival was 77% in HPV16+ and 66% in HPV16- OPC (P=0·03, Fig. 1b). The only other factor 
associated with OPC recurrence in the multivariable model was advanced stage disease (HR for stage IV OPC: 4.88; 95% CI: 2.12–11.21). 27% (22/82) of patients 
with HPV16+ OPC had recurrence within the follow-up period. Other factors associated with progression among HPV16+ OPC included moderate dental care (HR: 
3.98, 95% CI: 1.19–13.35) and advanced disease stage (HR for stage IV OPC: 7.54, 95% CI: 1.23–46.13). In this study, 198 corresponding tumors were available for 
321 cases and were tested for HPV DNA and p16 expression. The subset of 198 patients was similar to the entire cohort of 321 patients on all covariates examined 
including age, sex, smoking pack years, drink years, dental care score, BMI categories, stage and HPV16 E6 status. Of the 198, 16 were excluded due to limited 
tissue. Of the remaining 182 tumors, 153 tumors had valid HPV DNA as well as p16 overexpression scored. Of these, 51 were HPV16 E6 seropositive of which 43 
were positive for both HPV16 DNA and p16 expression while 44 were positive for p16 expression alone (Table 3). Among the 102 HPV16 E6 seronegative cases, 96 
were HPV16 DNA or p16 negative while 82 were p16 negative. The agreement between HPV16 E6 serology and the combined marker (91%) was better compared to 
p16 alone (82%) (Table 3). In the univariate analysis, tumor HPV16 DNA positivity alone was marginally associated with OPC survival (HR: 0.66, 95% CI: 0.43–
1.02), while tumor p16-positivity alone (HR: 0.59, 95% CI: 0.38–0.94) or dual positivity to HPV16 DNA and p16 (HR: 0.48, 95% CI: 0.29–0.81) were significantly 
associated with OPC survival. The strongest association with survival however, was observed among OPC subjects who were HPV16 E6 serology positive 
(HR=0.44, 95% CI: 0.26–0.74). In the fully adjusted model however, only the association between HPV16 E6 serology and OPC survival remained significant (HR: 
0.36, 95% CI: 0.19–0.71) (Table 4).  
 
Table 1 
Univariate and  multivariate analyses  of risk factors associated  with death in 321 oropharyngeal cancer patients. 
 
Univariate Multivariate 
 
 
Characteristics Dead/Total HR (95% CI) aHR (95% CI) 
   
 
 (N = 321) 
 
 
HPV16 E6 Serology 
Negative 136/222 1.0 1.0 
Positive 39/99 0.49 (0.34–0.70) 0.51 (0.32–0.80) 
Sex 
Male 147/247 1.0 1.0 
Female 28/74 0.52 (0.35–0.78) 0.50 (0.29–0.85) 
Age (10 year increase) 1.24 (1.05–1.45) 1.17 (0.95–1.44) 
Smoking statusa 
≤10 Pack-years 19/58 1.0 1.0 
> 10 Pack-years 155/262 2.24 (1.39–3.60) 1.11 (0.59–2.09) 
Alcohol useb 
≤2 drinks/day 75/159 1.0 1.0 
> 2 drinks/day 99/160 1.53 (1.13–2.06) 1.02 (0.69–1.51) 
Dental carec 
Good 36/84 1.0 1.0 
Moderate 134/231 1.58 (1.1–2.29) 1.09 (0.72–1.65) 
Poor 3/4 2.45 (0.76–7.98) 0.46 (0.06–3.44) 
BMI at diagnosisd 
Normal) 83/161 1.0 1.0 
Underweight 20/25 2.25 (1.38–3.67) 2.41 (1.38–4.21) 
Overweight 61/108 1.01 (0.73–1.41) 1.12 (0.77–1.63) 
Stagee 
I&II 22/71 1.0 1.0 
III 35/67 2.02 (1.18–3.44) 1.78 (1.02–3.10) 
IV 85/131 2.84 (1.78–4.55) 2.63 (1.61–4.30) 
aHR: adjusted mutually for all covariates in the table, and additionally  for  center of recruitment. 
a 1 case missing smoking information. 
b 2 cases missing alcohol data. 
c missing information on 2 cases. d missing information on 27 cases. e missing stage on 52 cases. 
 
 
Table 2 
Univariate and multivariate analyses of risk factors associated with recurrence  in 260 oropharynx cancer patients. 
Characteristics Recurrence/ 
Total 
HR (95% CI) aHR (95% CI) 
HPV16 E6 Serology     
Negative 62/178 1 1 
 
 
 
Positive 22/82 0.59 (0.36–0.96) 0.55 (0.29–1.06) 
Sex     
Male 63/197 1 1 
Female 21/63 0.86 (0.52–1.40) 1.04 (0.52–2.09) 
Age (10 year  1.13 (0.89–1.43) 1.03 (0.77–1.38) 
increase)    
Smoking status     
≤10 Pack-years 
> 10 Pack-years 
15/51 
68/208 
1 
1.38 (0.79–2.43) 
1 
0.65 (0.30–1.41) 
Alcohol use 
≤2 drinks/day 
 
41/134 
 
1 
 
1 
> 2 drinks/day 43/125 1.33 (0.87–2.04) 0.99 (0.55–1.81) 
Dental care 
Good 15/75 1 1 
Moderate 67/180 2.25 (1.29–3.95) 1.82 (0.96–3.45) 
Poor (0.23–13.42) 
BMI at diagnosis 
1.19 (0.15–9. 69) 
Normal 45/134 1 1 
Underweight 4/20 0.85  (0.30–2.36) 0.82   (0.27–2.43) 
Overweight 28/92 0.82 (0.51–1.32) 0.74 (0.43–1.27) 
Stage 
I & II 10/57 1 1 
III 18/67 2.12 (0.98–4.59) 2.89 (1.18–7.06) 
IV 40/105 3.22 (1.61–6.44) 4.88 (2.12–11.21) 
 
 
HR represents results from univariate cox models. 
aHR: adjusted mutually for all covariates in the table, and additionally  for  center of recruitment. 
 
 
 
Table 3 
Concordance between serology and tumor markers of HPV16 infection in 153 oropharyngeal cancer patients. 
 
HPV16 E6 serology 
 
 
 Positive Negative 
  
Tumor marker N = 51 N = 102 
 
  
HPV16 DNA/p16 status Agreement = 91% 
Positive 43 6 
Negative 8 96 
p16 status Agreement = 82% 
Positive 44 20 
Negative 7 82 
  
 
 
 
Table 4 
Multivariate analysis of the association between markers of HPV16 infection  and risk of death in 153 oropharyngeal cancer patients. 
HPV marker Dead/Total HR (95% CI) aHR (95% CI) 
HPV16 DNA 
Negative 
 
41/69 
 
1.0 
 
1.0 
Positive 41/84 0.66 (0.43–1.02) 0.77 (0.43–1.35) 
p16 
Negative 
 
54/89 
 
1.0 
 
1.0 
Positive 28/64 0.59 (0.38–0.94) 0.72 (0.42–1.24) 
HPV16 DNA/p16 
Negative 
 
63/102 
 
1.0 
 
1.0 
Positive 19/51 0.48 (0.29–0.81) 0.63 (0.35–1.15) 
HPV16 E6 
Negative 
 
63/104 
 
1.0 
 
1.0 
Positive 19/49 0.44 (0.26–0.74) 0.36 (0.19–0.71) 
aHR: adjusted for age, sex, smoking pack years, alcohol drink years, dental care, stage and center. 
 
Discussion  
 
This study confirms HPV16 status as an independent prognostic factor for overall survival and recurrence-free survival among OPC patients’. We also report that 
women are at lower risk of death (for both HPV+/HPV- OPC), while being underweight at diagnosis increases the risk of death following OPC diagnosis. The 
reduction in risk of death among HPV16+ OPC in this study was similar in magnitude to previous studies [11,27]. Our results indicate that additional factors may 
have an important effect in predicting survival following OPC. In particular that women may have approximately 50% reduced risk of death compared to men 
following an OPC diagnosis. Importantly, this benefit was extended to late stages of disease and was consistent for both HPV16+ and HPV16- OPC suggesting the 
 
 
 
protective effect may be driven by inherent factors. Although an individual's gender has been long recognized as a key factor affecting cancer incidence, prognosis, 
and treatment response, the underlying mechanisms remain poorly understood. We also report that being underweight at diagnosis increases the risk of death 
following OPC by over two-fold. This association was robust across stage, sex and HPV16 status. Although it remains probable that low BMI at diagnosis reflects the 
disease itself, since cancer patients tend to lose weight rapidly following disease onset, it could also point towards the need for nutritional interventions prior to 
clinical treatment as a strategy towards potentially improved outcomes. The lack of association with low BMI at 30 years of age and OPC survival in this study (data 
not shown) supports this notion. It remains important to note that both low BMI at diagnosis as well as female sex remained independently associated even when 
considering the recently proposed prognostic risk classification for OPC. These findings warrant further validation in independent studies. For OPC recurrence, the 
only factor significantly associated was higher stage at diagnosis. Previous studies have found tobacco smoking to be independently associated with overall survival 
as well as progression-free survival among OPC patients [5,11,28,29]. Smoking, in particular, 10 or 20 pack year thresholds in conjunction with tumor stage and HPV 
status have therefore been proposed for risk stratification and [11,29] to identify patients who may benefit from treatment de-escalation. In this study, the lack of 
association between smoking and OPC survival was consistently observed irrespective of the smoking parameter examined (i.e., smoking status, or varying 
definitions for pack years including increments of 1 pack year, 10 pack years or thresholds of 10 and 20 pack years). Sequential adjustment of covariates indicates that 
HPV16 status and disease stage could potentially account for the survival differences due to smoking. Further, we found no interaction between smoking and HPV16 
status in the risk of death following OPC. These results call for additional evidence in larger cases series in order to accurately establish the role of smoking and 
survival among HPV16+ OPC. This study demonstrates a strong association between HPV16 status and OPC survival. Even though p16 and HPV16 DNA each 
showed utility in predicting mortality, they both appeared to be sub-optimal proxies for HPV16 status. While the utility of tumor HPV16 DNA and p16 as diagnostic 
markers of OPC is now well established [30–32], this study confirms the utility of HPV16 E6 serology as a prognostic marker and may be potentially useful for risk-
stratification of OPC. Based on the definition for HPV positivity used in this study (HPV16 E6 seropositive), we classified 6 HPV DNA+ and p16+ cases that were 
HPV16 E6- as HPV negative cases. We concede that these could potentially reflect false negative cases for HPV16 E6 serology, larger studies will be required to 
better understand the molecular and clinical behaviour of such rare subsets. Despite the advantage of the multi-centric design and the large number of participants 
enrolled in the parent study, the OPC subset was limited to 321 cases. Even so, to the best of our knowledge, this remains among the largest analysis of this rare 
cancer with detailed information on risk factors, patient outcome as well as HPV16 status. Important strengths of this study are the centralized testing for HPV16, 
uniform collection of survey and cancer outcome information in all centers. Some of the limitations include the absence of detailed treatment information that could 
potentially impact survival. However, the majority of the patients’ were treated with surgery alone or in conjunction with chemotherapy or radiation therapy (68%). 
Further, disease stage was missing on 16% of OPC since the study was initially designed with a focus on risk factors for cancer occurrence, therefore comprehensive 
collection of clinical data was not emphasized. In conclusion, this study confirms the markedly improved prognosis associated with HPV+ OPC in Europe. In 
addition, we report that being female and low BMI at diagnosis are important factors affecting overall OPC survival. Further large studies that also include 
comprehensive mutational profiling will be required to better understand the mechanisms underlying these prognostic subgroups.  
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